On Wednesday, September 28, Buchanan Life Sciences will be holding its first-ever Product Portfolio Optimization Summit for in-house attorneys and corporate practitioners.
This will consist of a full day of in-person CLE programming designed for decision-makers of life sciences companies. With the impact on product portfolios at the forefront, topics will range from election year issues on the table, enhancing approval tactics, optimized strategies for product acquisition and divestiture, key antitrust issues in litigation, compliance and more. The summit will also include a solution-focused Diversity & Inclusion program on attracting and retaining diverse talent within the Life Sciences space.
Agenda Topics Include:
Election Year Presentation: Issues Impacting Life Sciences Companies & Their Portfolios
Michael Strazzella, Senior Principal, Government Relations, Buchanan Ingersoll & Rooney
Crossing the Approval Divide: Cohesive Strategies from Concept Through Reimbursement
Edward John Allera, Co-Head, Life Sciences Practice, Buchanan Ingersoll & Rooney
Tom Evegan, Principal, Strategy & Management Consulting, RSM